AI Chip to Help Capture and Analyze Molecular Data in RT
By LabMedica International staff writers Posted on 28 Nov 2017 |
Image: The system-on-chip is designed to yield highly-secure molecular data, which can be used in the recognition and analysis of health threats caused by pathogens and other living organisms (Photo courtesy of Nano Global).
Molecular data company Nano Global (Austin, TX, USA) is developing a chip using intellectual property (IP) from Arm Holdings (Cambridge, UK), a semiconductor IP company, to help redefine how global health challenges ranging from superbugs to infectious diseases, and cancer are conquered. The pioneering system-on-chip (SoC) will yield highly-secure molecular data, which can be used in the recognition and analysis of health threats caused by pathogens and other living organisms.
The chip, combined with the company's scientific technology platform, leverages advances in nanotechnology, optics, artificial intelligence (AI), blockchain authentication, and edge computing to access and analyze molecular-level data in real time. The initial development of the chip is underway and the first delivery is expected by 2020, with the company having already begun adding new partners to their platform.
"In partnership with Arm, we're tackling the vast frontier of molecular data to unlock the unlimited potential of this universe," said Steve Papermaster, Chairman and CEO of Nano Global. "The data our technology can acquire and process will enable us to create a safer and healthier world."
"We believe the technology Nano Global is delivering will be an important step forward in the collective pursuit of care that improves lives through the application of technology," said Rene Haas, executive vice president and president of IPG, Arm. "By collaborating with Nano Global, Arm is taking an active role in developing and deploying the technologies that will move us one step closer to solving complex health challenges."
Nano Global will also be partnering with several leading institutions, including Baylor College of Medicine and National University of Singapore, on broad research initiatives in clinical, laboratory, and population health environments to accelerate data collection, analysis, and product development.
Related Links:
Nano Global
Arm Holdings
The chip, combined with the company's scientific technology platform, leverages advances in nanotechnology, optics, artificial intelligence (AI), blockchain authentication, and edge computing to access and analyze molecular-level data in real time. The initial development of the chip is underway and the first delivery is expected by 2020, with the company having already begun adding new partners to their platform.
"In partnership with Arm, we're tackling the vast frontier of molecular data to unlock the unlimited potential of this universe," said Steve Papermaster, Chairman and CEO of Nano Global. "The data our technology can acquire and process will enable us to create a safer and healthier world."
"We believe the technology Nano Global is delivering will be an important step forward in the collective pursuit of care that improves lives through the application of technology," said Rene Haas, executive vice president and president of IPG, Arm. "By collaborating with Nano Global, Arm is taking an active role in developing and deploying the technologies that will move us one step closer to solving complex health challenges."
Nano Global will also be partnering with several leading institutions, including Baylor College of Medicine and National University of Singapore, on broad research initiatives in clinical, laboratory, and population health environments to accelerate data collection, analysis, and product development.
Related Links:
Nano Global
Arm Holdings
Latest Industry News
- Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests
- CACLP 2025 New Date and Venue Announced
- Roche to Develop New Diagnostic Technologies for Traumatic Brain Injuries
- LGC Clinical Diagnostics and AccuGenomics Collaborate on Enhancing Cancer Testing Accuracy
- Beckman Coulter and SphingoTec Partner to Improve Kidney Health Assessment in Critical Care
- Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative
- Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance
- MEDICA LABMED FORUM 2024: International Experts Meet to Discuss Trending Topics in Laboratory Medicine
- Nova Biomedical and Terumo BCT Collaborate on Automated Cell Culture Sensing
- Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
- Roche Expands Digital Pathology Open Environment with Integration of Advanced AI Algorithms from New Collaborators
- Qiagen and Eli Lilly to Develop First QIAstat-Dx IVD Panel for Neurodegenerative Applications
- QIAGEN and AstraZeneca Expand Collaboration into New Disease Areas
- MEDICA 2024 + COMPAMED 2024: Adapted Hall Layout for Better Integration
- Global Coagulation Testing Driven by Increasing Blood Disorders and Surgical Interventions
- Sysmex and QIAGEN Expand Collaboration in Genetic Testing